Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells

One mechanism of resistance of prostate cancer (PCa) to enzalutamide (MDV3100) treatment is the increased expression of AR variants lacking the ligand binding-domain, the best characterized of which is AR-V7. We have previously reported that Phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5Kα),...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarwar, Martuza, Semenas, Julius, Miftakhova, Regina, Simoulis, Athanasios, Robinson, Brian, Wingren, Anette Gjörloff, Mongan, Nigel P., Heery, David M., Johnsson, Heather, Abrahamsson, Per-Anders, Dizeyi, Nishtman, Luo, Jun, Persson, Jenny L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325347/
https://www.ncbi.nlm.nih.gov/pubmed/27588408
http://dx.doi.org/10.18632/oncotarget.11757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325347/
https://www.ncbi.nlm.nih.gov/pubmed/27588408
http://dx.doi.org/10.18632/oncotarget.11757

Ejemplares similares